ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

Martin Hutchings et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.